Glenmark Pharma to launch a Triple FDC for Diabetes in India; stock rises ~7%

21 Dec 2022 , 02:14 PM

Glenmark Pharmaceuticals Limited launched the first triple fixed-dose combination of Teneligliptin, Pioglitazone, and Metformin in India. Teneligliptin is a well-known DPP4 (Dipeptidyl Peptidase 4) inhibitor.

The company has launched this FDC under the brand name Zita – PioMet. Reportedly, the FDC contains, Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation.

The FDC is ideal for patients with Type 2 diabetes. These patients can benefit from once-daily dosing to improve glycemic control and achieve the target HbA1c in 24 weeks.

Glenmark has a long history of developing new, effective, and cost-effective treatment options for diabetic patients, particularly those with uncontrolled Type 2 diabetes.

According to IQVIA sales data for the 12-month period ending November 2022, oral anti-diabetic drugs in India is has an estimated market size of Rs 11,877 crore, representing a 6.3% annual growth over the previous year. 

At around 2.03 PM, Glenmark Pharma was trading 6.63% higher at Rs 437.65, against previous close of Rs 409.25 on NSE. The counter hit intraday high and low of Rs 441.40 and Rs 410.05 respectively.

For feedback and suggestions, write to us at [e-mail]